These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30161279)

  • 1. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase.
    Goyal S; Jamal S; Shanker A; Grover A
    J Cell Biochem; 2019 Jan; 120(1):768-777. PubMed ID: 30161279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
    Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
    J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
    Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
    J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach.
    Zhao Z; Bourne PE
    J Chem Theory Comput; 2020 May; 16(5):3152-3161. PubMed ID: 32283024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations.
    He MY; Li WK; Meiler J; Zheng QC; Zhang HX
    Biopolymers; 2019 Feb; 110(2):e23257. PubMed ID: 30664251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
    Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
    Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
    Ni Z; Zhang TC
    J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
    Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
    Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role and targeting of anaplastic lymphoma kinase in cancer.
    Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
    Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
    Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
    Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase.
    Ashinuma H; Shingyoji M; Hasegawa Y; Yokoi S; Yoshida Y
    Intern Med; 2018 Nov; 57(21):3153-3155. PubMed ID: 29877262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
    Singhi EK; Horn L
    Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
    Zhu VW; Cui JJ; Fernandez-Rocha M; Schrock AB; Ali SM; Ou SI
    Lung Cancer; 2017 Aug; 110():32-34. PubMed ID: 28676215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics.
    Chen J; Wang W; Sun H; Pang L; Yin B
    J Comput Aided Mol Des; 2020 Dec; 34(12):1289-1305. PubMed ID: 33073300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.
    Li J; Huang Y; Wu M; Wu C; Li X; Bao J
    Sci Rep; 2018 Jul; 8(1):10664. PubMed ID: 30006516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R.
    Mathi GR; Kang CH; Lee HK; Achary R; Lee HY; Lee JY; Ha JD; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
    Eur J Med Chem; 2017 Jan; 126():536-549. PubMed ID: 27915169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review.
    Zhao X; Feng Z; Wang G; Pang H; Wang M
    Clin Lung Cancer; 2018 Nov; 19(6):e945-e956. PubMed ID: 30228011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.